SCHEMBL771031

SCHEMBL771031

O=C(C=Cc1ccccc1)NCCC(=O)N1CCC2CCCCC2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 2/20 0.53
BCHE P06276 4/20 0.48
ACHE P22303 4/20 0.48
MMP1 P03956 1/20 0.46
POLB P06746 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
RECQL P46063 1/20 0.46
APP P05067 1/20 0.46
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
HPGD P15428 2/20 0.45
MAPT P10636 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771029 1.00 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AALDH1A1LMNABCHE
SCHEMBL771449 0.81 KMT2A (0.50) SMN1; SMN2KMT2AALDH1A1LMNABCHE
SCHEMBL771447 0.81 KMT2A (0.50) SMN1; SMN2KMT2AALDH1A1LMNABCHE
SCHEMBL770493 0.81 KDM4E (0.53) SMN1; SMN2KMT2AALDH1A1RAB9A
SCHEMBL771597 0.79 ALDH1A1 (0.49) SMN1; SMN2KMT2AALDH1A1POLBHPGD
SCHEMBL771030 0.76 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AALDH1A1LMNABCHE
SCHEMBL771711 0.76 LMNA (0.49) SMN1; SMN2KMT2AALDH1A1LMNAHPGD
SCHEMBL770899 0.76 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1LMNARAB9A
SCHEMBL771552 0.75 KMT2A (0.54) SMN1; SMN2KMT2AALDH1A1LMNABCHE
SCHEMBL771125 0.75 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AALDH1A1LMNAHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3653/4885KMT2A 3868/4885ALDH1A1 144/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3637/4885KMT2A 3893/4885ALDH1A1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.